Acelrx Pharmaceuticals Inc IPO-Jahr
Was ist das IPO-Jahr von Acelrx Pharmaceuticals Inc?
IPO-Jahr von Acelrx Pharmaceuticals Inc ist 2011
Was ist die Definition von IPO-Jahr?
Börsengang ist ein öffentliches Angebot, bei dem Aktien eines Unternehmens normalerweise an institutionelle Anleger verkauft werden, die ihrerseits erstmals an einer Wertpapierbörse an die breite Öffentlichkeit verkauft werden.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
IPO-Jahr von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Acelrx Pharmaceuticals Inc
Was macht Acelrx Pharmaceuticals Inc?
acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v
Unternehmen mit ipo-jahr ähnlich Acelrx Pharmaceuticals Inc
- Goldman Sachs Mutual Fund - Goldman Sachs Nifty Exchange Traded Scheme hat IPO-Jahr von 2010
- Software Effective Solutions hat IPO-Jahr von 2010
- GINSMS hat IPO-Jahr von 2010
- Photonike Capital SA hat IPO-Jahr von 2010
- Parabolic Drugs hat IPO-Jahr von 2010
- West Kirkland Mining hat IPO-Jahr von 2010
- Acelrx Pharmaceuticals Inc hat IPO-Jahr von 2011
- Omineca Mining and Metals hat IPO-Jahr von 2012
- iShares Asia Trust - iShares Core CSI 300 Index ETF hat IPO-Jahr von 2012
- Wendy`s Co hat IPO-Jahr von 2012
- Unisys hat IPO-Jahr von 2012
- Christopher & Banks hat IPO-Jahr von 2012
- Wellesley hat IPO-Jahr von 2012